New hope for Obesity-Linked endometrial cancer: experimental combo enters human trials
NCT ID NCT05542407
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests the safety of combining two drugs, ONC201 and atezolizumab, in 58 women with advanced or recurrent endometrial cancer. The study includes both obese and non-obese participants to see if body weight affects treatment. The goal is to find the best dose and check for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ONC201 and atezolizumab
- What this could lead to
- If this combination proves safe and effective, it could offer a new treatment option for women with advanced endometrial cancer, especially those with obesity.
- What could go wrong
- This is an early Phase 1 trial with only 58 participants, focused on safety and dosing. The drugs may not shrink tumors or may cause serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOSARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Lineberger Comprehensive Cancer Center
RECRUITINGChapel Hill, North Carolina, 27599, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- What raises endometrial cancer risk in black women? a study digs in
- Can immunotherapy plus hormones spare the womb in early endometrial cancer?
- Can a new drug tackle Hard-to-Treat gynecologic cancers?
- Can a pill restore the Body's tumor suppressor to fight multiple cancers?
- Could gentle yoga and breathing ease Cancer's lingering toll?